During the observation period, eight myeloma patients (4%, four in each cohort; Plerixafor Group: one melanoma, one prostate cancer, one lung adenocarcinoma, one renal cell carcinoma; G-CSF Group: one Hodgkin’s lymphoma, two melanomas, and one t-AML) and six (5%) lymphoma patients developed a secondary malignancy after ASCT (five in the Plerixafor Group: one non-small-cell lung carcinoma, one myelodysplastic syndrome, three other lymphomas, and one in the G-CSF Group with a myeloproliferative neoplasm) (Table 3 and Table 4). The gene discussed is CSF3; the disease is prostate cancer.